Trial Profile
A Study to Assess the Safety and Efficacy of MK0364 in Obese Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Taranabant (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 28 Jul 2008 Status changed from in progress to completed, as reported on clincialtrials.gov
- 25 Oct 2005 New trial record.